The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease

Martins IJ*

1Centre of Excellence in Alzheimer’s Disease Research and Care School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, 6027, Australia.

2School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Nedlands, 6009, Australia.

3McCusker Alzheimer’s Research Foundation, Hollywood Medical Centre, 85 Monash Avenue, Suite 22, Nedlands, 6009, Australia.

*Correspondence: Ian Martins, School of Medical Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia 6027, Australia, Tel: +61863042574, E-mail: i.martins@ecu.edu.au.

Received: 01 September 2017; Accepted: 23 September 2017


Keywords
Biomarkers, Diagnosis, Genomic, Immunometabolism, Mitochondria.

Abbreviations
NAFLD: Nonalcoholic fatty liver disease, MODS: Multiple organ disease syndrome, Sir 1: Sirtuin 1, LPS: Bacterial lipopolysaccharides.

Editorial
Interests in global organ diseases have accelerated with links between nonalcoholic fatty liver disease (NAFLD) and various chronic diseases with relevance to the metabolic syndrome and neurodegenerative diseases. Early diagnosis of global organ disease involve genomic, lipidomic and proteomic biomarker tests that may diagnose early neuron dysfunction with the prevention of various organ diseases [1]. Diet and nutrition are closely linked to accelerated aging and may allow biomarker tests to provide adequate information with relevance to the immune system dysfunction and the severity of chronic diseases. In spite of various biomarker tests and analyte measurements for chronic diseases such as obesity and diabetes abnormal nuclear-mitochondria interactions [2] persist with inflammation involved in the induction of programmed cell death.

Various diagnostic technologies have been used with relevance to genomics, lipidomics and proteomics to generate heat maps [3-5] that may allow more sensitive interpretations of cell dysfunction. Analysis of plasma lipidomic and proteome heat maps in NAFLD, obesity and diabetes are required to determine relationship between these heat maps (lipid/protein interactions) with relevance to genomic heat maps. The diagnostic technologies encompass the genome, transcriptome, proteome and metabolome (central dogma of biology, Wikipedia) and determine the cell genome and transcription factor alterations with relevance to concentrations of plasma lipids and proteins [6]. The projected cost of plasma and cell biomarker analysis is expected to cost by the year 2012 approximately 52 billion dollars [7]. Major efforts with proteomic biomarkers have identified plasma protein panels to assess progression and severity of diseases with relevant proteomic biomarkers that delay the severity of progression from mild cognitive impairment to prodromal disease and dementia [8]. Lipidomics and genomics have become important as technologies that may supersede proteomic biomarker tests with the analysis of plasma ceramides and sphingolipids that may be relevant to single gene inactivation [1,9] and multiple organ dysfunction syndrome (MODS).

Interests in genomic tests and autoimmune disease have accelerated with Sirtuin 1 (Sirt 1) inactivation associated with immunometabolism defects and related to defective heat shock protein metabolism and natural killer cell activation [10-14] linked to NAFLD. Genomic biomarkers in predictive medicine [15] must now include nuclear, cytoplasmic and plasma Sirt 1 analysis to avoid expensive diagnostic technologies (Figure 1) with biomarker analysis that do not assess the severe progression of cell disease that involve mitochondrial apoptosis. Mitophagy is now relevant to various chronic diseases such as NAFLD, obesity, diabetes and Alzheimer’s disease [16-18]. Diet and nutrition have become important to the immune system and mitophagy with the correct...
consumption of fat critical to maintain the nuclear-mitochondria interaction [19] with the prevention of mitochondrial apoptosis and cell death.

![Heat Shock Proteins and Drug Metabolism](image)

**Figure 1**: Various diagnostic technologies for biomarker analysis may not assess the severe progression of cell disease that involve mitochondrial apoptosis. Altered biological interactions, immune system dysfunction and cell lipid metabolism defects do not reflect the sensitivity of various biomarker test assays. Altered plasma micro RNA levels and cell transcription factors may not be connected to increased heat shock proteins that induce natural killer cell activation with mitochondrial apoptosis. Diagnostic technologies for biomarker analysis may now also need assays for LPS, xenobiotic, magnesium and calcium that are associated with nutritional disturbances.

Technologies that cost billions of dollars have become of major concern with relevance to inadvertent errors that may not allow early interpretations of disease progression that may be irreversible. In the developing world bacterial lipopolysaccharides (LPS) levels [20] should be carefully assessed to prevent repression of Sirt 1 with complete nitric oxide and immune dysregulation related to mitophagy, MODS and global organ disease [9,15,20]. Plasma heat shock protein analysis [14] is relevant to immune dysregulation and associated with inactivation of the heat shock gene Sirt 1 needs measurement to avoid unexpected errors with relevance to various biomarker tests (Figure 1). The relevance of LPS that may corrupt magnesium, calcium and albumin formulas may be require recalculation [15] with relevance to the biomarker test limitations with relevance to severity of inflammatory pathways for various chronic diseases [21]. Proteomic, lipidomic and genomic biomarker test should be carefully interpreted with relevance to individuals from the developed world that visit or stay in the developing world with mitophagy in these individuals associated with xenobiotic toxicity [22].

**Conclusion**

Diagnostic technologies for biomarker analysis have become important to the immune system and mitophagy to prevent early programmed cell death. Projected costs for biomarker analysis is expected to increase to billions of dollars in the next few years but altered biological and cell membrane interactions may not allow early diagnosis of immune system dysfunction related to early progression of global organ disease. In the developing world LPS and xenobiologic levels may be responsible for altered biological interactions and supersede diagnostic technologies for biomarker analysis. Inactivation of Sirt 1 by increased ceramide levels and nutritional disturbances may be responsible for increased inflammation (autoimmune disease) and mitophagy in NAFLD and global chronic disease.

**Acknowledgements**

This work was supported by grants from Edith Cowan University, the McCusker Alzheimer's Research Foundation and the National Health and Medical Research Council.

**References**


